Zellbasierte Therapeutika zur Behandlung der Osteoarthritis beim Pferd

Roth, Susanne Pauline; Brehm, Walter; Troillet, Antonia

doi:10.1055/a-1482-7752

Cited by 1 publication

(5 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs can be derived from mesenchymal tissues such as blood, bone marrow and adipose tissue, but do not represent a homogeneous stem cell population (41). In horses, commonly used MSC sources are fat, harvested from subcutaneous adipose tissue at the tail base (lipectomy) (54,55), bone marrow obtained by puncturing the sternum (56) or venous blood (40,57).…”

Section: Mesenchymal Stromal Cellsmentioning

confidence: 99%

“…In horses, commonly used MSC sources are fat, harvested from subcutaneous adipose tissue at the tail base (lipectomy) (54,55), bone marrow obtained by puncturing the sternum (56) or venous blood (40,57). Following tissue harvesting, the process of MSC isolation and cultivation under laboratory conditions requires several weeks to obtain cell numbers usually used for intra-articular applications (41). Besides these autologous cultivated MSCs, commercially available MSC therapeutics are approved by the European Medicines Agency (EMA).…”

Section: Mesenchymal Stromal Cellsmentioning

confidence: 99%

“…These so-called point-of-care products are readily available through a fast, standardized process of cell separation and MSC enrichment by medical devices (27,62). Depending on the tissue sources and processing, the final solution contains a variety of different cell types in a mixed population of blood and adipose progenitor cells as well as differentiated cells (41,42). The proportion of MSC-like cells within the final product is regarded low and not defined (63).…”

Section: Mesenchymal Stromal Cellsmentioning

confidence: 99%

“…Platelet rich plasma (PRP) is one of the bestknown representatives of this therapeutic group, with a defined 3-to 5-fold increase in platelet concentration in autologous plasma (73,74). PRP is produced using a double-centrifugation method (41). Alternative processing methods such as singlecentrifugation techniques and filtration provide therapeutics with deviating values of platelets and leucocytes from PRP (33,75).…”

Section: Autologous Blood Productsmentioning

confidence: 99%

“…After more than 20 years of clinical experience in equine medicine, the use of intra-articularly applied orthobiologic therapeutics is considered as a safe and recognized treatment option for osteoarthritic joints today (41,42). Yet, existing studies, which form the basis of our knowledge about the efficacy of orthobiologic therapeutics in equine medicine, differ in fundamental study design parameters like the availability of placebo groups or the type of researched OA (naturally occurring vs. experimentally induced OA).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Systematic review and meta-analysis of positive long-term effects after intra-articular administration of orthobiologic therapeutics in horses with naturally occurring osteoarthritis

Mayet

Zablotski²,

Roth

et al. 2023

Front. Vet. Sci.

Self Cite

View full text Add to dashboard Cite

Equine veterinarians face challenges in treating horses with osteoarthritic joint pain in routine veterinary practice. All common treatment options aim to reduce the clinical consequences of osteoarthritis (OA) characterized by persistent synovitis and progressive degradation of articular cartilage. A range of joint-associated cell types and extracellular matrices are involved in the not yet entirely understood chronic inflammatory process. Regeneration of articular tissues to re-establish joint hemostasis is the future perspective when fundamental healing of OA is the long-term goal. The use of intra-articular applied biologic therapeutics derived from blood or mesenchymal stroma cell (MSC) sources is nowadays a well-accepted treatment option. Although this group of therapeutics is not totally consistent due to the lack of clear definitions and compositions, they all share a potential regenerative effect on articular tissues as described in in vivo and in vitro studies. However, the current stage of science in regenerative medicine needs to be supported by clinical reports as in fact, in vitro studies as well as studies using induced OA models still represent a fragment of the complex pathomechanism of naturally occurring OA. This systemic review aims to determine the long-term effect of orthobiologic therapeutics in horses suffering naturally occurring OA. Thereby, a meta-analysis of randomized controlled trials (RCTs) is conducted to describe the efficiency and safety of intra-articular applied orthobiologics in terms of lameness reduction in the long-term. Using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines, thirteen studies met the inclusion criteria for the systemic review. Four of those studies have further been evaluated by the meta-analysis comparing the long-term effect in lameness reduction. Each study was examined for risk of bias. For data evaluation, a random-effects model was used, describing the overall outcome in a forest plot. The I2 statistic was used to assess heterogeneity. Results indicate, that orthobiologic therapies represent an effective long-term and safe OA treatment option. Due to the inhomogeneity of included studies, no statements are provided addressing specific orthobiologic therapies, affected joints, OA stage and horse's intended use. Future clinical trials should follow standardized study designs to provide comparable data.

show abstract

Section: Mesenchymal Stromal Cellsmentioning

confidence: 99%